News Image

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

Provided By GlobeNewswire

Last update: May 16, 2025

Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes

Read more at globenewswire.com

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (9/19/2025, 8:00:02 PM)

After market: 2.27 -0.01 (-0.44%)

2.28

-0.22 (-8.8%)



Find more stocks in the Stock Screener

CAMP Latest News and Analysis

Follow ChartMill for more